High Rates of SVR Demonstrated in Phase II Study with Investigational Triple DAA Regimen of Daclatasvir, Asunaprevir and BMS-791325 in Treatment-NaÃ¯ve Patients with Genotype 1 Chronic Hepatitis C Infection